pyrroles has been researched along with Diarrheogenic Islet Cell Tumor in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bourcier, ME; Vinik, AI | 1 |
| Brixi, H; Cadiot, G; de Mestier, L; Lombard-Bohas, C; Walter, T | 1 |
2 other study(ies) available for pyrroles and Diarrheogenic Islet Cell Tumor
| Article | Year |
|---|---|
Sunitinib for the treatment of metastatic paraganglioma and vasoactive intestinal polypeptide-producing tumor (VIPoma).
Topics: Abdominal Neoplasms; Aged; Antineoplastic Agents; Biomarkers, Tumor; Child; Drug Administration Schedule; Female; Humans; Indoles; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Magnetic Resonance Imaging; Male; Pancreatic Neoplasms; Paraganglioma; Protein Kinase Inhibitors; Pyrroles; Sunitinib; Time Factors; Treatment Outcome; Vipoma | 2013 |
Sunitinib achieved fast and sustained control of VIPoma symptoms.
Topics: Adult; Antineoplastic Agents; Fatal Outcome; Female; Humans; Indoles; Male; Middle Aged; Pancreatic Neoplasms; Pyrroles; Sunitinib; Time Factors; Vipoma | 2015 |